Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting
- Written by PR Newswire
- The abstract of BBT-207 preclinical studies is now available on the AACR website
- Preclinical data suggests that BBT-207 may have the potential to be used as a broad-spectrum fourth generation EGFR TKI with anti-tumor effects in EGFR mutant NSCLC
- An investigational new drug application for the first-in-human study in patients will be submitted by 1H...